Prescribing information

PRRT Practical Resources

Peptide receptor radionuclide therapy (PRRT) is a form of radioligand therapy (RLT) used to treat neuroendocrine tumours (NETs).1 Click here to learn more about RLT.

In PRRT targeting NETs, a cell-targeting protein, similar to the naturally occurring hormone somatostatin, is combined with a radionuclide to deliver targeted radiation to somatostatin receptor-expressing tumour sites.1

Octreotide (DOTATOC) and octreotate (DOTATATE) are two examples of targeting peptides used in PRRT. Due to their similarity to the naturally occurring hormone somatostatin, they are often referred to as somatostatin analogues (SSA). These SSAs are combined with therapeutic radionuclides, such as lutetium-177 (Lu-177).1

Click on the resources below to learn more about PRRT.

1. Bodei L, et al. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
AAA-Lu177-UK-2157 | October 2023

Ask Speakers


Medical Information Request